Lilly's eczema drug shows durable long-term response in late-stage study

Eli Lilly said on Friday that its eczema drug showed durable ‌results in a late-stage post-marketing study, ‌such as relief from persistent itch for up to four years in ​patients with the skin condition.

Here are more details:

* A once-monthly injection of the drug, Ebglyss - approvedin the United States in 2024 - showed durable response ‌inpatients with moderate-to-severe ⁠atopic dermatitis, which causesintense itching. * The injectable treatment is approved for adults andchildren ⁠12 years and older with moderate-to-severe eczema whocannot use topical therapies. * In the study, majority ​of patients ​achieved near-completeskin clearance ​and itch relief with ‌up to four years ofcontinuous treatment, Lilly said. * Ebglyss' safety in the first year of the study wasconsistent with its known profile, regardless of dosingfrequency, and no new safety issues were ‌observed, the companysaid. * The study ​will continue for an ​additional year oftreatment. * Lilly ​last year reported results from another ‌trialshowing Ebglyss provided a ​durable response ​when dosed everyfour or eight weeks. The drugmaker said it has submitted thedata to ​the U.S. Food ‌and Drug Administration for a potentiallabel update.

https://www.yahoo.com/news/articles/lillys-eczema-drug-shows-durable-135620304.html